EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma

Rafael Jiménez, Andrada Constantinescu, Muhube Yazir, Paula Alfonso-Triguero, Raquel Pequerul, Xavier Parés iD, Mileidys Pérez-Alea iD, Ana Paula Candiota iD, Jaume Farrés iD, Julia Lorenzo iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252111512 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Rafael Jiménez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Faculty of Biosciences, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia, Innovación y Universidades, Agència de Gestió d'Ajuts Universitaris i de Recerca, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GB) is an aggressive malignant central nervous system tumor that is currently incurable. One of the main pitfalls of GB treatment is resistance to the chemotherapeutic standard of care, temozolomide (TMZ). The role of aldehyde dehydrogenases (ALDHs) in the glioma stem cell (GSC) subpopulation has been related to chemoresistance. ALDHs take part in processes such as cell proliferation, differentiation, invasiveness or metastasis and have been studied as pharmacological targets in cancer treatment. In the present work, three novel α,β-acetylenic amino thiolester compounds, with demonstrated efficacy as ALDH inhibitors, were tested in vitro on a panel of six human GB cell lines and one murine GB cell line. Firstly, the expression of the ALDH1A isoforms was assessed, and then inhibitors were tested for their cytotoxicity and their ability to inhibit cellular ALDH activity. Drug combination assays with TMZ were performed, as well as an assessment of the cell death mechanism and generation of ROS. A knockout of several ALDH genes was carried out in one of the human GB cell lines, allowing us to discuss their role in cell proliferation, migration capacity and resistance to treatment. Our results strongly suggest that ALDH inhibitors could be an interesting approach in the treatment of GB, with EC50 values in the order of micromolar, decreasing ALDH activity in GB cell lines to 40–50%.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideGlioblastomaHumansCell Line, TumorAnimalsCell ProliferationMiceAntineoplastic Agents, AlkylatingBrain NeoplasmsRetinal DehydrogenaseDrug Resistance, NeoplasmAldehyde DehydrogenaseReactive Oxygen SpeciesCell Movement

Stichwörter der Autor:innen

aldehyde dehydrogenasecancerenzyme inhibitionglioblastomaretinoic acid

Substanzen

TemozolomideAntineoplastic Agents, AlkylatingRetinal DehydrogenaseAldehyde DehydrogenaseReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, Faculty of Biosciences, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain.
  • Institute for Biotechnology and Biomedicine, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain.
  • Unit of Research in Cellular and Molecular Biology, Advanced BioDesign, Saint-Priest, 69800 Lyon, France.
  • Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, E-08193 Bellaterra, Spain.
  • Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, E-08913 Bellaterra, Spain.

ORCID-Profile: Xavier Parés, Mileidys Pérez-Alea, Ana Paula Candiota, Jaume Farrés, Julia Lorenzo

Förderung

  • Ministerio de Ciencia, Innovación y Universidades
  • Agència de Gestió d'Ajuts Universitaris i de Recerca
  • Instituto de Salud Carlos III
  • Spanish Ministerio de Ciencia e Innovación
  • Agència de Gestió d’Ajuts Universitaris i de Recerca

Zitieren

APA

Jiménez, R., Constantinescu, A., Yazir, M., Alfonso-Triguero, P., Pequerul, R., Parés, X., Pérez-Alea, M., Candiota, A. P., Farrés, J., & Lorenzo, J. (2024). Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252111512

Vancouver

Jiménez R, Constantinescu A, Yazir M, Alfonso-Triguero P, Pequerul R, Parés X, et al. Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252111512

BibTeX
@article{Jimnez2024,
  author = {Jiménez, Rafael and Constantinescu, Andrada and Yazir, Muhube and Alfonso-Triguero, Paula and Pequerul, Raquel and Parés, Xavier and Pérez-Alea, Mileidys and Candiota, Ana Paula and Farrés, Jaume and Lorenzo, Julia},
  title = {Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252111512}
}
Kostenlos starten →